NCT04724629View on ClinicalTrials.gov

Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

March 31, 2021

Study Completion Date

July 30, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

Ixekizumab

80 mg of IL-17 inhibitor

BIOLOGICAL

Aldesleukin

1.5 million IU (low-dose) of IL-2

DRUG

Colchicine

0.5 mg of indirect IL-6 inhibitor

DRUG

Standard of care (SOC)

Active comparator (Corticoids and antiretrovirals)

Trial Locations (2)

Unknown

Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto

09030-010

Hospital e Maternidade Christovão da Gama, Santo André

All Listed Sponsors
collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

collaborator

Science Valley Research Institute

OTHER

lead

University of Sao Paulo

OTHER

NCT04724629 - Survival TRial Using CytoKines in COVID-19 (STRUCK Trial) | Biotech Hunter | Biotech Hunter